培美曲塞联合顺铂治疗晚期非小细胞肺癌26例近期疗效观察

Clinical observation of pemetrexed combined with cisplatin treated advanced non-small cell lung cancer

目的观察培美曲塞联合顺铂治疗晚期非小细胞肺癌的临床疗效和不良反应。方法 26例晚期非小细胞肺癌患者采用培美曲塞500 mg/m2,静脉滴注,第l天;顺铂75 mg/m2,静脉滴注,第l天,2l d为1个周期,2个周期后评价疗效及不良反应。结果全组26例患者均可评价疗效。其中CR 1例,PR 5例,SD 11例,PD 9例,有效率23.1%(6/26)。结论培美曲塞联合顺铂治疗晚期非小细胞肺癌的近期疗效较好,毒副反应低,提高了患者的生活质量。

Objective To investigate the objective response rate, and toxicity of pemetrexed combined with cisplatin for advanced non-small cell lung cancer（NSCLC）. Methods： twenty-six patients with advanced NSCLC were administrated with pemetrexed 500 mg/m^2 iv gtt dl and cisplatin 75 mg/m^2 iv gtt dl, 1 cycle were 21 days. The treatment was finished after 2-4 cycles. Results Response and toxicity could be assessed in all the 26 patients. One patient achieved complete response （ CR ） , 5 cases partial response （PR）, 11 cases stable disease （SD）, 9cases progression disease （PD）. The overall response rate was 23.1% （6/26）. Conclusion Pemetrexed combined with cisplatin regimen showed higher response rate and manageable toxicity, and improved the quality of life in patients with advanced non-small cell lung cancer